The majority of published studies show that oestrogen receptor (ER) status in breast cancer is completely predictive neither for prognosis nor for responsiveness to endocrine treatment (for review see Thorpe, 1988) . Two hypotheses have been proposed to explain the lack of response to endocrine therapy in patients with ER+ tumours: (1) the tumour is heterogeneous and expressed both ER+ and ER-cell clones; (2) ER could be defective; the receptor protein, although capable of interacting with its specific hormone, might not activate the sequence of events responsible for the ultimate hormonal effect. Indeed, histochemical studies clearly demonstrate that a high percentage, if not all, of ER+ tumour samples shown heterogeneous ER expression (Arvan, 1992) . However, the simultaneous determination of ER by both biochemical and histochemical methods could improve the predictive value of ER status. On the other hand, defective forms of ER molecules have been recently demonstrated (Fuqua et al., 1991; Sluyser & Wittliff, 1992) .
Regarding this latter aspect, cell products synthesised under oestrogen control have been thoroughly investigated (Adams et al., 1983) . Their expression would indeed indicate an effective ER machinery. The determination of progesterone receptor (PgR), which is synthesised under oestrogen control (Horwitz & McGuire, 1978) , provided additional information concerning prognosis and responsiveness to endocrine therapies. However, despite many published studies, there is still much controversy regarding the usefulness of PgR in addition to ER. Indeed, about 20% of ER+ PgR + cases did not respond to endocrine therapy (Thorpe, 1988) . Further, several authors have shown that PgR is a better prognostic factor than ER (Clark et al., 1983; Alexieva-Figush et al., 1988) , whereas others have found that the predictive value of ER overcomes that of PgR (Rayter, 1991; Aaltomaa et al., 1991) . Most likely, ER and PgR have a different prognostic meaning in different subgroups of patients (Thorpe, 1988 Among the oestrogen regulated parameters, the human pS2 gene, which is specifically transcribed under oestrogen control (Jacowlew et al., 1984) , has been identified in MCF-7 breast cancer cell lines by Masiakowski et al. (1982) . The pS2 gene has been cloned and the encoded protein identified as an 84 amino acid secreted protein whose functions are still unknown (Masiakowski et al., 1982; Nunez et al., 1987; .
Using monoclonal antibodies, the pS2 protein was detected in about 50% of breast cancers where it showed a cytoplasmatic staining with a tendency to perinuclear condensation (Henry et al., 1991) .
Preliminary studies showed that the pS2 positivity is mainly restricted to samples expressing ER (Rio et al., 1987; Foekens et al., 1990; Schwartz, 1991) and is predictive for a better prognosis (Foekens et al., 1990) . Conversely, Henry et al. using an immunohistochemical method did not find a significant correlation between pNR-2/pS2 staining and time to relapse or overall survival (Henry et al., 1991) . More recent data (Predine et al., 1992) , showed that pS2 is expressed also in a fraction of ER negative tumours and that the prognostic value of pS2 is limited to cases with very low levels of the protein, which indeed showed a poorer prognosis.
In the present study we evaluated pS2 protein in relation to steroid receptor status, cathepsin D and the cytosol levels of the tumour marker tissue polypeptide antigen, that belongs to the cytokeratin family (Mellerick et al., 1990) . The two latter cytoplasmic proteins are prognostic indicators in patients with breast cancer (Spyratos et al., 1989 , Gion et al., 1993 .
Materials and methods
Four hundred and forty-six patients with primary breast cancer have been evaluated. Inclusion criteria were as follows:
(1) stage 1-3 infiltrating breast carcinoma; (2) no previous or concomitant malignancies of other organs; (3) no older than 75 years of age; (4) no irradiation, chemotherapy or endocrine therapy prior to surgery. Patients whose last menstrual cycle occurred less than 2 years previously were included in the peri-menopausal group; 100 (24.3%) patients were pre-, 33 (Gion et al., 1986 clonal antibody anti-pS2 and 0.2 ml of standard or diluted cytosol samples are dispensed into test tubes coated with a second anti-pS2 monoclonal antibody. After incubation for 1 h at room temperature under agitation, samples are washed three times with distilled water and bound radioactivity is counted. Within-assay and between-assay variability was excellent, the coefficient of variation among 20 determinations of the same cytosol sample being lower than 5%. The accuracy of the assay was evaluated using the dilution test (Yalow & Berson, 1968) applied to several cytosol samples. The recovery ranged from 90 to 101% with a dilution factor ranging from 1:1 to 1:1280. The protein concentration was determined using the Coomassie brilliant blue method (Bio-Rad, Richmond, CA, USA). The cytosolic parameters examined were expressed in relation to mg of cytosolic protein.
Considering that few clinical data on the most reliable positive/negative cutoff point for pS2 are so far available, we categorised pS2 in tumour samples using two criteria.
(1) In some instances we subdivided the distribution of levels of pS2, cathepsin D, ER and PgR into three groups (below the 40th percentile, between the 40th and the 60th percentile and above the 60th percentile value of the distribution found in tumour samples). The Pearson x2 statistic was thus applied.
(2) Conversely, for the assessment of the relation between pS2 and prognosis we chose a single +/-cutoff point selected with the graphic method first described by Tandon et al. (1990) . Several pS2 values are plotted against the P value of the differences of percentage of relapse and death between pS2+ and pS2-cases. In the examined patient series, the most effective pS2 value capable of discriminating between good and poor prognosis was 4 ng mg-' cytosolic protein for both relapse-free survival (RFS) and overall survival (OS) (Figure 1 ). The same method for the identification of the best cutoff point has been previously used for the evaluation of the prognostic value of the other parameters studied in the present investigation (Gion et al., 1993) . The relapse-free survival (RFS) and the overall survival (OS) were calculated by the Kaplan-Meier product limit method. Analysis of RFS and OS were performed using the logrank univariate (Peto et al., 1977) and the Cox multivariate method (Cox, 1972) . All computations were carried out using the BMDP statistical software.
Results pS2 distribution in tumour samples examined was not Gaussian (Kolmogorov-Smirnov test P <0.001). Using the cutoff point of a 4 ng mg' I cytosolic protein calculated as previously described, 177 cases (59.6%) were pS2 + and 120 (40.4%) pS2-in the 297 patients in which the prognosis was evaluable (all the evaluated prognostic factors were available in 267 cases). In the entire series the distribution of pS2 + and pS2 -cases was not significantly different, the figures being 248 (55.6%) and 198 (44.4%) respectively. pS2 levels and age, menopausal status, tumour size, nodal status, cathepsin D and cTPA No significant associations were found between pS2 levels and age, tumour size and the number of positive lymph nodes.
pS2 was significantly higher in pre -(median 20.2 ng mg-l cytosolic protein, interquartile 2.9-55.6) than in peri-(median 5.6 ng mg-cytosolic protein, interquartile 0.7-19.1) and in post-menopause (median 4.0 ng mg' cytosolic protein, interquartile 0.9-25.2, P = 0.0001).
The association between pS2 and cathepsin D, although statistically significant using both linear correlation and Spearman Rank correlation (both P < 0.001), was weak as shown by the regression coefficients (linear regression r= 0.281, Spearman r= 0.166). Table I summarises the distribution of pS2 in relation to cathepsin D status. Patients were subdivided into three groups according to cathepsin D levels using the same criteria used for pS2 (below the 40th percentile, between 40th and 60th percentile and above the 60th percentile value). A slightly but significantly higher frequency of cases with elevated pS2 occurred in samples in which cathepsin D was higher.
No relationships were found between pS2 and cTPA. (Table IV) .
pS2+ patients showed a longer RFS and OS than pS2- (Figures 1 and 2) . After stratification according to several variables, pS2+ cases showed a better prognosis than pS2-only in some subgroups of patients (Table V) (Cox, 1972 (Table VI) .
The most effective prognostic indicators after the nodal (Tubiana & Koscielny, 1991) . Therefore, the management of patients with breast cancer requires the identification of reliable prognostic parameters in order to evaluate the risk of recurrence in N-patients (Ingle, 1991) . Moreover, the frequency of N-cases, which is close to 50%, is expected to further increase as a consequence of early diagnosis and screening programme (Duffy et al., 1991) . Several potentially prognostic biological parameters have been evaluated or are under investigation (Foekens et al., 1991) . The use of a panel of prognostic parameters should be advisable because to date an 'absolute' prognostic factor has not yet been identified (Ingle, 1991; Foekens et al., 1991) . The choice of the parameters to include in the panel should take into consideration several items (Ingle, 1991) (Rio et al., 1987; Foekens et al., 1990; Schwartz et al., 1991; Predine et al., 1992) . Partially conflicting findings are reported by Henry et al. (1991) , who used an immunohistochemical technique and found a significant association between pNR-2/pS2 positivity and both low histological grade and smaller tumour size.
The present study confirms that pS2 is an effective prognostic factor in some subgroups of patients with breast cancer. Our data show a more limited prognostic difference between pS2+ and pS2-cases than Foekens et al. (1990) , who however used a much higher cutoff point. Conversely, our data are more in agreement with those of Predine et al. (1992) , although their prognostic cutoff point is much lower than ours. Probably, differences in assay methods may justify at least in part the different cutoff points found in the three different studies. Thus Predine et al. (1992) used an ELISA method that recorded levels of pS2 lower than those measured in our series by IRMA. Foekens et al. (1990) used an IRMA method with loose components. The pS2 standard was not as highly purified as that of the commerically available IRMA kit used in the present study (Foekens et al., 1991 al., 1991; Predine et al., 1992) . In the present study the multivariate analysis suggests that pS2 and ER information overlap. The two parameters seem therefore alternative prognostic indicators. However, the association between pS2 and steroid receptors, although evident, is not absolute, which is in agreement with findings of other authors (Schwartz et al., 1991; Henry et al., 1991; Predine et al., 1992) . Analysing individual patients, the proportion of pS2-cases in the ER + or PgR + group is elevated. Further follow up data are necessary to verify if in these cases, pS2 really indicates a group with poor prognosis. The pS2 + cases which occur in the ER -and/or PgRpatients are also of relevance. Their frequency is close to figures found by Henry et al. (1991) and Predine et al. (1992) and higher than that found by Foekens et al. (1990) . The pS2 + ER-PgR-phenotype, although occurring in a limited percentage of cases, may provide clinically useful information because the expression of pS2 may be indicative of a functioning ER machinery. This seems confirmed in the present study by the favourable prognostic behaviour of pS2+/ER-or PgRcases.
Other mechanisms may be implicated in the regulation of pS2 expression, however. It has been shown that pS2 gene transcription is oestrogen independent in stomach mucosa, probably being regulated by EGF or c-Ha-ras and c-jun proteins (Nunez et al., 1989; Wright et al., 1990) .
To our knowledge, no published data are available concerning the association between pS2 and cathepsin D. We demonstrate here that cathepsin D level correlate weakly with pS2. This could have been expected since both are somewhat under oestrogen control (Jacowlew et al., 1984; Westley, 1987) . However, the multivariate analysis clearly demonstrated that cathepsin D and pS2 provided independent prognostic information. Moreover, pS2 is an effective prognostic indicator in both cathepsin+ and cathepsin-cases.
In the present study pS2 is also independent of cytosol TPA, which is related to steroid receptors (Gion et al., 1986) and provides effective prognostic information in breast cancer (Gion et al., 1993) .
From the present findings we can draw the following conclusions:
(1) in patients which breast cancer pS2 is a prognostic parameter independent of tumour size, nodal status, cathepsin D and cTPA; (2) concentrations of pS2 are not closely related to ER or PgR concentrations in individual patients; (3) in the present series the prognostic information provided by pS2 seems to be more effective than that of ER and/or PgR alone; (4) although further studies are needed to confirm these findings in a wider patient series, pS2 does not provide an alternative to steroid receptors for the assessment of endocrine status of the tumour.
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